S&S On Biotech
Conversations on the science and business of Biotechnology with Andy Smith and Cormac Sheridan.
To receive notifications when new episodes are published, email notifications@smithandsheridan.eu or follow us on LinkedIn.
S&S On Biotech
2.2 Recent Biotech Acquisitions. Done Already, or More to Come?
The annual JP Morgan Healthcare Conference, held in San Francisco every January, marks the start of the biotech industry’s new year. It’s the time when biotechnology companies of all shapes and sizes set out their stall for the year ahead, hoping to attract the attention – and the dollars – of big pharma.
It’s the ideal time to take the temperature of the industry. And right now, it appears to be emerging from the big chill of 2023. The Nasdaq Biotechnology Index continues the climb it began in Q4 2023, deals continue to get done, and companies continue to raise cash. And new conversations that lead to future deals get started. Much of the swagger that characterised the meeting during the boom years has gone – and that’s no bad thing. But for those who have struggled to stay afloat during the past year, a recovery will be welcome.
Companies mentioned in this episode:
Aiolos Bio, Ambryx, Amgen, AstraZeneca, Bristol Myers Squibb, Cellarity, Eli Lilly, GSK, Isomorphic Labs, Johnson & Johnson, Omega Therapeutics, Pfizer, Novartis, Novo Nordisk, Rayzebio, Roche, & Seagen
Suggestion box (Suggestions on future episodes, points for clarification, comments, etc.)
Subscribe (Get notified when new episodes are available. NO marketing!)
Follow us on LinkedIn
Disclaimer
